Search
ILY101
go.drugbank.com/drugs/DB05059InvestigationalILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract.
Thymoquinone
go.drugbank.com/drugs/DB16447InvestigationalThymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial.
NB-001
go.drugbank.com/drugs/DB12716InvestigationalNB-001 has been investigated for the treatment of Recurrent Herpes Labialis.
Subasumstat
go.drugbank.com/drugs/DB16406Investigationalor Metastatic Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)). … Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced
GR270773
go.drugbank.com/drugs/DB06427Investigationalinfusion between healthy adults and those with damaged livers) and NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a
Amniotic Epithelial Cells
go.drugbank.com/drugs/DB15868InvestigationalAmniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus. These cells are potential candidates for allogeneic cell ...
MDX-1379
go.drugbank.com/drugs/DB05329InvestigationalMDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.
Nangibotide
go.drugbank.com/drugs/DB16247InvestigationalNangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).
GTI-2501
go.drugbank.com/drugs/DB05406ExperimentalGTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. … The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer.